Revere Pharmaceuticals
Dr. Goka is a translational biologist with over 15 years of research experience. His research has focused on understanding the molecular mechanisms of how oncogenes and tumor-suppressor genes control signaling pathways leading to initial cellular transformation, tumor formation, tumor progression, metastatic dissemination, and resistance to conventional therapy. Dr. Goka was part of the team that discovered that HACE1, the E3 ubiquitin ligase for Rac1, is an important tumor-suppressor gene commonly lost in the progression of breast cancer.
Prior to Revere, Dr. Goka was Senior Director of Preclinical Development at Geneyus, LLC, where he led a team developing small molecule Rac1 inhibitors and authored multiple publications investigating the biological mechanisms of Rac1signaling and how Rac1 inhibition can overcome resistance to standard-of-care treatment options.
This person is not in any offices
Revere Pharmaceuticals
Revere Pharmaceuticals is a Boston-based startup leading the way in the development of new cancer treatments targeting Rac1 GTPase, an important target in the progression of different cancers. R-ketorolac, their lead candidate, is a first-in-class Rac1 inhibitor that shows both clinical and non-clinical evidence of efficacy in ovarian cancer.